Colgate-Palmolive (CL) PT Raised to $80.00 at Citigroup

Colgate-Palmolive (NYSE:CL) had its target price upped by Citigroup from $75.00 to $80.00 in a research report issued to clients and investors on Tuesday. The firm currently has a “neutral” rating on the stock. Citigroup’s price objective would indicate a potential upside of 7.14% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Zacks Investment Research upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $81.00 price objective for the company in a research note on Monday, October 23rd. Deutsche Bank initiated coverage on Colgate-Palmolive in a research note on Wednesday, December 13th. They set a “hold” rating and a $75.00 price objective for the company. KeyCorp restated a “hold” rating on shares of Colgate-Palmolive in a research note on Monday, October 16th. Macquarie upgraded Colgate-Palmolive from a “neutral” rating to an “outperform” rating and set a $81.00 price objective for the company in a research note on Tuesday, December 19th. Finally, Stifel Nicolaus set a $73.00 price objective on Colgate-Palmolive and gave the stock a “hold” rating in a research note on Sunday, October 29th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $77.48.

Shares of Colgate-Palmolive (NYSE CL) traded up $0.88 during midday trading on Tuesday, hitting $74.67. The company had a trading volume of 6,027,481 shares, compared to its average volume of 3,500,000. The company has a quick ratio of 0.34, a current ratio of 0.47 and a debt-to-equity ratio of 24.42. The stock has a market cap of $65,570.00, a PE ratio of 32.75, a P/E/G ratio of 3.06 and a beta of 0.81. Colgate-Palmolive has a 1 year low of $63.95 and a 1 year high of $77.91.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, January 26th. The company reported $0.75 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.75. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Colgate-Palmolive had a return on equity of 1,716.69% and a net margin of 13.10%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 EPS. analysts predict that Colgate-Palmolive will post 3.16 EPS for the current year.

In other news, insider Victoria L. Dolan sold 10,000 shares of the stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $73.07, for a total value of $730,700.00. Following the transaction, the insider now directly owns 60,528 shares of the company’s stock, valued at $4,422,780.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen I. Sadove sold 20,780 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $70.52, for a total value of $1,465,405.60. Following the completion of the transaction, the director now directly owns 36,268 shares in the company, valued at $2,557,619.36. The disclosure for this sale can be found here. Insiders have sold a total of 181,950 shares of company stock worth $13,237,385 over the last ninety days. 1.02% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Bessemer Group Inc. increased its holdings in shares of Colgate-Palmolive by 1.1% in the fourth quarter. Bessemer Group Inc. now owns 2,410,394 shares of the company’s stock valued at $181,865,000 after purchasing an additional 25,822 shares during the period. Fulcrum Capital LLC acquired a new position in shares of Colgate-Palmolive in the fourth quarter valued at about $204,000. Welch Investments LLC increased its holdings in shares of Colgate-Palmolive by 8.0% in the fourth quarter. Welch Investments LLC now owns 65,681 shares of the company’s stock valued at $4,956,000 after purchasing an additional 4,848 shares during the period. Braun Stacey Associates Inc. boosted its stake in shares of Colgate-Palmolive by 38.9% in the fourth quarter. Braun Stacey Associates Inc. now owns 93,990 shares of the company’s stock worth $7,091,000 after buying an additional 26,335 shares during the last quarter. Finally, Price Wealth Management Inc. purchased a new stake in shares of Colgate-Palmolive in the fourth quarter worth about $213,000. 72.96% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Colgate-Palmolive (CL) PT Raised to $80.00 at Citigroup” was originally published by American Banking and Market News and is the property of of American Banking and Market News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/30/colgate-palmolive-cl-pt-raised-to-80-00-at-citigroup.html.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.